Floatz logo

Evomela

Myelodysplastic/Myeloproliferative Neoplasms

M.D. Anderson Cancer CenterPhase 2/3Active
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
95/ 100

Competitive context

45 Active assets in the Myelodysplastic/Myeloproliferative Neoplasms cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BBB
Cytosin-Arabinosid
Fred Hutchinson Cancer Center
Phase 3BBB
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
Busulphan
Jacqueline Garcia, MD
Phase 2/3BBB
Anti-Thymoglobulin, Rabbit
M.D. Anderson Cancer Center
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Evomela is also rated in:

diffuse large B-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
myeloproliferative neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →